An interventional study of Interventions for Stressful Transitions in Later Life (InSTILL) for Individuals in Nursing Home Resident, Skilled Nursing Facility and Depression, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies in Depression by Massachusetts General Hospital — 24 open to participants now, 33 under way, none of them phase 3. Depression · Massachusetts General Hospital.
Among the 163 studies in Depression by Massachusetts General Hospital, this one is the 122nd largest by planned enrollment of the 153 interventional ones that give a count, is one of 12 that started in 2025, is one of 100 with no phase, reaches primary completion later than 5 of the 32 other live ones, and was the 160th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →24 of the 163 studies in Depression by Massachusetts General Hospital are open now, in 4 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in Nigeria
Ages 16–29
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 22 · Phase 3 9 · Phase 4 22
First in 2001; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 60 across the 153 interventional studies, 80 across the 10 observational. Of the 123 that completed or were terminated, 71 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
20 of the studies in Depression by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06094088Massachusetts General HospitalResearching Heat and Yoga for Mood Enhancement | 2026-12 |
| NCT04832685Massachusetts General HospitalNeuromodulation of Mind-Wandering in Depression | 2026-12 |
| NCT07892287Massachusetts General HospitalEffect of Neurofeedback and TMS | 2027-01 |
| NCT07639827Massachusetts General HospitalA Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion | 2027-01 |
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 163 studies in Depression by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test a behavioral health program (Interventions for Stressful Transitions in Later Life, InSTILL, for Individuals) for skilled nursing facility residents. The main questions it aims to answer is whether the program is program is feasible, satisfactory, and helpful. Participants will join 6 bi-weekly sessions of the InSTILL program. Participants will complete assessments at three timepoints (all) and a brief-exit interview.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm will participate in the Interventions for Stressful Transitions in Later Life (InSTILL), a behavioral health intervention tailored to the needs of short stay nursing facility residents. InSTILL for Individuals includes 6 sessions (2x per week for about 3 weeks) delivered in person or remotely.
Behavioral: Interventions for Stressful Transitions in Later Life (InSTILL) for Individuals
The Interventions for Stressful Transitions in Later Life (InSTILL) intervention is for skilled nursing facility residents experiencing elevated levels of psychological distress. The intervention is designed to improve life management skills and emotion regulation skill with the goal of reducing depression symptoms.
Mean Total Score Treatment Credibility
3-item self-report measure of participant's belief regarding how helpful the intervention will be for them. Higher scores (min = 0, max = 30) scores indicate greater credibility.
Time frame: After session 1 of intervention, an average of 1 week after baseline
Mean Total Score Client Satisfaction Questionnaire
3-item self-report measure assessing patient satisfaction with the program. Higher total scores (min = 3, max = 12) indicate greater satisfaction.
Time frame: Post intervention, an average of 4 weeks after baseline
Percentage of Eligible Participants Enrolled
Percentage of eligible approached individuals that are enrolled into the study.
Time frame: Post intervention, an average of 4 weeks after baseline
Percentage of Participants with Missing Data
Percentage of all participants with no measure fully missing at 4-week follow-up.
Time frame: 4 weeks after post-intervention
Attendance Rate
Percentage of participants completing 4/6 sessions of the intervention.
Time frame: Post intervention, an average of 4 weeks after baseline
Clinician Fidelity
Percentage of InSTILL sessions delivered with 100% adherence on a study-specific Fidelity Checklist, based on those randomly sampled to be assessed.
Time frame: Post intervention, an average of 4 weeks after baseline
Number of Adverse Events
Number of adverse events related to participation in the study.
Time frame: 4 weeks after post-intervention
Treatment Acceptability Survey
Percentage of participants scoring above the scale midpoint on all Treatment Acceptability Survey items (developed for the current study).
Time frame: Post intervention, an average of 4 weeks after baseline
Percentage of Participants Meeting Participant Comprehension Criterion
Percentage of participants scoring 7+ on a single-item cognitive load question (min=0, max=10)
Time frame: Post intervention, an average of 4 weeks after baseline
Patient Health Questionnaire-9
9-item self-report measure of depression symptoms. Higher scores (min=0, max=27) indicate greater depressive symptoms.
Time frame: Baseline; Post intervention, an average of 4 weeks after baseline; 4 weeks after post-intervention
Selection, Optimization, and Compensation (SOC) in Everyday Use
4-item self-report measure of the application of selection, optimization, and compensation strategies in daily life. Items are averaged for a composite score, with higher scores indicate greater SOC strategy use (Range = 1-6).
Time frame: Baseline; Post intervention, an average of 4 weeks after baseline; 4 weeks after post-intervention
Committed Action Questionnaire
8-item self-report measure of pursuit of valued goals despite challenges and difficulties. Higher scores indicate greater use and effectiveness of emotional regulation skills (Range = 0-48).
Time frame: Baseline; Post intervention, an average of 4 weeks after baseline; 4 weeks after post-intervention
General Anxiety Disorder-7
7-item self-report measure of anxiety symptoms. Higher scores indicate higher levels of anxiety symptoms (Range = 0-21).
Time frame: Baseline; Post intervention, an average of 4 weeks after baseline; 4 weeks after post-intervention
Euro QoL-5D 5L
6-item self-report measure of subjective health-related quality of life. Higher scores indicate worse health-related quality of life (Range = 5-25). The scale also includes a separately scored single-item global health indicator, asked on a 0-100 scale with higher scores indicate higher subjective health-related quality of life.
Time frame: Baseline; Post intervention, an average of 4 weeks after baseline; 4 weeks after post-intervention
COREQ
4-item self-report of nursing facility satisfaction. Higher averaged scores indicate greater facility satisfaction (Range = 1-5).
Time frame: Post intervention, an average of 4 weeks after baseline
University of Washington Resilience Scale Short Form
4-item self-report of an individual's perceived resilience. Summed scores will be converted to T-scores using a conversion table.
Time frame: Baseline; Post intervention, an average of 4 weeks after baseline; 4 weeks after post-intervention
Psychotropic medication use
Chart or self reported psychotropic medication use. Patients will self-report changes to medication, including dosage, at post-intervention and follow-up
Time frame: Baseline; Post intervention, an average of 4 weeks after baseline; 4 weeks after post-intervention
Re-hospitalization
Resident re-hospitalization during the study period
Time frame: Post intervention, an average of 4 weeks after baseline; 4 weeks after post-intervention
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 13 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Oct 2026 → Jan 2027 and completion Dec 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →